These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 1583867)
1. Maple syrup urine disease: interrelations between branched-chain amino-, oxo- and hydroxyacids; implications for treatment; associations with CNS dysmyelination. Treacy E; Clow CL; Reade TR; Chitayat D; Mamer OA; Scriver CR J Inherit Metab Dis; 1992; 15(1):121-35. PubMed ID: 1583867 [TBL] [Abstract][Full Text] [Related]
2. Diagnosis and treatment of maple syrup disease: a study of 36 patients. Morton DH; Strauss KA; Robinson DL; Puffenberger EG; Kelley RI Pediatrics; 2002 Jun; 109(6):999-1008. PubMed ID: 12042535 [TBL] [Abstract][Full Text] [Related]
3. Renal clearance of branched-chain L-amino and 2-oxo acids in maple syrup urine disease. Schadewaldt P; Hammen HW; Ott AC; Wendel U J Inherit Metab Dis; 1999 Aug; 22(6):706-22. PubMed ID: 10472531 [TBL] [Abstract][Full Text] [Related]
4. Prospective study of maple-syrup-urine disease for the first four days of life. DiGeorge AM; Rezvani I; Garibaldi LR; Schwartz M N Engl J Med; 1982 Dec; 307(24):1492-5. PubMed ID: 7144815 [No Abstract] [Full Text] [Related]
6. Thiamin-responsive maple syrup urine disease: seizures after 7 years of satisfactory metabolic control. Delis D; Michelakakis H; Katsarou E; Bartsocas CS J Inherit Metab Dis; 2001 Nov; 24(6):683-4. PubMed ID: 11768588 [No Abstract] [Full Text] [Related]
7. The relationship between the branched chain amino acids and their alpha-ketoacids in maple syrup urine disease. Snyderman SE; Goldstein F; Sansaricq C; Norton PM Pediatr Res; 1984 Sep; 18(9):851-3. PubMed ID: 6483508 [TBL] [Abstract][Full Text] [Related]
8. Correlations between branched-chain amino acids and branched-chain alpha-keto acids in blood in maple syrup urine disease. Langenbeck U; Wendel U; Mench-Hoinowski A; Kuschel D; Becker K; Przyrembel H; Bremer HJ Clin Chim Acta; 1978 Sep; 88(2):283-91. PubMed ID: 699323 [TBL] [Abstract][Full Text] [Related]
9. Dysmyelination in the brain of adolescents and young adults with maple syrup urine disease. Schönberger S; Schweiger B; Schwahn B; Schwarz M; Wendel U Mol Genet Metab; 2004 May; 82(1):69-75. PubMed ID: 15110325 [TBL] [Abstract][Full Text] [Related]
10. Plasma amino acid analyses in two cases of maple syrup urine disease. Surarit R; Srisomsap C; Wasant P; Svasti J; Suthatvoravut U; Chokchaichamnankit D; Liammongkolkul S Southeast Asian J Trop Med Public Health; 1999; 30 Suppl 2():138-9. PubMed ID: 11400750 [TBL] [Abstract][Full Text] [Related]
11. Functional differences in the catabolism of branched-chain L-amino acids in cultured normal and maple syrup urine disease fibroblasts. Schadewaldt P; Wendel U Biochem Med Metab Biol; 1989 Apr; 41(2):105-16. PubMed ID: 2719855 [TBL] [Abstract][Full Text] [Related]
12. So-called thiamin-responsive maple syrup urine disease: 15-year follow-up of the original patient. Scriver CR; Clow CL; George H J Pediatr; 1985 Nov; 107(5):763-5. PubMed ID: 4056978 [No Abstract] [Full Text] [Related]
13. Nutritional deficiency dermatitis related to branched-chain amino acid restriction in a child with maple syrup urine disease. Campuzano-García AE; Castanedo-Cázares JP Dermatol Online J; 2019 Sep; 25(9):. PubMed ID: 31738841 [TBL] [Abstract][Full Text] [Related]
14. [3 patients with maple syrup urine disease]. Merinero B; del Valle JA; García MJ; García Miguel MJ; Barrio MI; García Hortelano J; Morales E; González F; García Aparicio J; Sáez Pérez E An Esp Pediatr; 1983 Nov; 19(5):393-400. PubMed ID: 6660657 [TBL] [Abstract][Full Text] [Related]
15. Electroencephalograms in a case of maple syrup urine disease: their relation to serum levels of branched-chain amino acids. Iinuma K; Saito T; Wada Y; Onuma A; Takamatsu N Tohoku J Exp Med; 1976 Oct; 120(2):191-5. PubMed ID: 982436 [TBL] [Abstract][Full Text] [Related]
16. Quantification of branched-chain amino acids in blood spots and plasma by liquid chromatography tandem mass spectrometry for the diagnosis of maple syrup urine disease. Sowell J; Pollard L; Wood T J Sep Sci; 2011 Mar; 34(6):631-9. PubMed ID: 21328532 [TBL] [Abstract][Full Text] [Related]
17. Maple syrup urine disease variant form: presentation with psychomotor retardation and CT scan abnormalities. Verdu A; Lopez-Herce J; Pascual-Castroviejo I; Martinez-Bermejo A; Ugarte M; Garcia MJ Acta Paediatr Scand; 1985 Sep; 74(5):815-8. PubMed ID: 4050430 [TBL] [Abstract][Full Text] [Related]
18. Dual mechanism of brain injury and novel treatment strategy in maple syrup urine disease. Zinnanti WJ; Lazovic J; Griffin K; Skvorak KJ; Paul HS; Homanics GE; Bewley MC; Cheng KC; Lanoue KF; Flanagan JM Brain; 2009 Apr; 132(Pt 4):903-18. PubMed ID: 19293241 [TBL] [Abstract][Full Text] [Related]
19. Successful pregnancy in maple syrup urine disease: a case report and review of the literature. Grünert SC; Rosenbaum-Fabian S; Schumann A; Schwab KO; Mingirulli N; Spiekerkoetter U Nutr J; 2018 May; 17(1):51. PubMed ID: 29753318 [TBL] [Abstract][Full Text] [Related]
20. Reduction of large neutral amino acid concentrations in plasma and CSF of patients with maple syrup urine disease during crises. Wajner M; Coelho DM; Barschak AG; Araújo PR; Pires RF; Lulhier FL; Vargas CR J Inherit Metab Dis; 2000 Jul; 23(5):505-12. PubMed ID: 10947205 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]